top of page

GALEAS® Bladder

Original price

£699.00

Sale price

£499.00

GALEAS® Bladder is an advanced, non-invasive urine test designed to help detect bladder cancer with high accuracy. Using targeted next-generation sequencing (NGS) technology, it analyzes tumor-associated genetic mutations found in urine — offering a convenient alternative to more invasive diagnostic procedures.

Simple sample collection, laboratory-grade genomic analysis, and clear clinical reporting make GALEAS® Bladder a modern solution for early detection, monitoring, and improved patient care.

Shipment

Haematuria - I confirm I have visible or non visible blood in my urine

Up to 5 characters.

Gender

Up to 5 characters.

Biomarkers checked

Genes tested:

AKT1, ERBB2, NRAS,BRAF, ERBB3 ,PIK3CA
C3orf70, ERCC2, RHOB
CDKN1A, FBXW7, RXRA
CDKN2A, FGFR3, SF3B1
CREBBP, HRAS, TERT (promoter)
CTNNB1, KDM6A, TP53
ELF3, KRAS

Further information regarding these genes can be found here

Biomarkers were identified by Prof Rik Bryan and Dr Doug Ward at Birmingham
University, UK.
• NGS sequencing panel that targets promoter and exonic regions of 23 of the
most relevant genes associated with bladder cancer
• Identified by a combination of publicly available data and deep exome
sequencing
• Exome studies were performed on Caucasian populations
• 451 somatic mutations present in the panel have been shown to detect 96%
of bladder cancers in over 644 clinical samples.

Key Features

  • A non-invasive genetic urine test for detecting bladder cancer across all stages and grades, with performance comparable to cystoscopy.

  • Uses targeted next-generation sequencing (NGS) to identify changes in up to 451 mutations linked with bladder cancer.

  • Can be conducted from home with a simple urine sample — no hospital visit needed.

  • Designed to streamline diagnostic pathways, potentially reducing unnecessary cystoscopies and associated costs.

Collection Method

Urine sample collection

  • Patients provide a urine sample using a bar-coded collection device.

  • Sample is then sent to the laboratory for genomic DNA extraction and ultra-sensitive NGS analysis.

  • The process is simple, non-invasive, and suitable for at-home collection.

Report Contents

Your report typically includes:

  • Positive/Negative diagnostic result for bladder cancer risk.

  • Interpretation of genomic biomarkers detected through NGS analysis.

  • Summary guidance for clinical follow-up (e.g., referral for further investigation when indicated).

  • Turnaround time information (from receipt of sample to report).

Scientific Technology

GALEAS® Bladder is based on molecular biomarker detection using next-generation sequencing (NGS):

  • Targets key somatic mutations in at least 23 genes associated with bladder cancer.

  • Utilizes ultra-sensitive targeted NGS chemistry developed to detect tumor-derived DNA in urine.

  • Analytical performance has been validated in multiple clinical cohorts, demonstrating high sensitivity and specificity across all cancer stages.

  • Cloud-based bioinformatics delivers streamlined analysis and reporting.

 

What’s Included

When you purchase the test:

  • Urine collection kit with barcoded device.

  • Pre-paid return postage for sample submission.

  • Laboratory processing of your sample using the GALEAS® Bladder workflow.

  • Secure electronic report delivered via email.

  • Clear instructions and clinical support information included.

 

Accreditation

GALEAS® Bladder is processed within accredited clinical laboratory environments operating under internationally recognised quality standards, including ISO 15189 (Medical Laboratories – Quality and Competence) and ISO 13485 (Medical Devices – Quality Management Systems).

All testing is conducted within regulated facilities to ensure analytical accuracy, quality assurance, and secure handling of patient data.

bottom of page